Alcon, a division of Novartis, has acquired Tear Film Innovations, Inc.  a privately-held company and manufacturer of the iLux Device, an innovative therapeutic device used to treat Meibomian Gland Dysfunction, a leading cause of dry eye.

Hand-held and portable, the iLux device enables eye-care professionals to directly target a patient’s blocked meibomian glands and provide therapy through an in-office treatment.

The Tear Film acquisition expands Alcon’s portfolio of ocular-health products, including several treatments for the temporary relief of dry eye symptoms.
Using the iLux Device, a practitioner can warm the eyelids via disposable silicone pads to address blocked meibomian glands through the application of light-based heating. While applying the iLux device, the practitioner can view the eyelid margin and apply manually-controlled compression to express blockages, making adjustments as needed to tailor treatment to the individual needs of the patient.

Most treatments can be completed in a matter of minutes.
The iLux Device received 510(k) clearance from the U.S. Food and Drug Administration in December 2017, and was officially launched by Tear Film in May 2018 at the annual meeting of the American Society for Cataract and Refractive Surgery.